NCR Online Journal

cMyc Proto-Oncogene Protein Inhibitor Pipeline

DelveInsight’s cMyc Proto-Oncogene Protein Inhibitor pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Key Takeaways from the cMyc Proto-Oncogene Protein Inhibitor Pipeline Report

• There are currently 5+ drugs in the cMyc Proto-Oncogene Protein Inhibitor pipeline.

• The cMyc Proto-Oncogene Protein Inhibitor pipeline consists of therapies in different clinical phase stages, including RRx-001, OMO- 103, WP-1066, APTO 253, ES-4000, and others.

• Leading companies actively working to improve the cMyc Proto-Oncogene Protein Inhibitor treatment landscape are EpicentRx, Peptomyc, Moleculin Biotech, Aptose Biosciences, Escend Pharmaceuticals, and others.

• EpicentRx announced in July 2020 that they had entered into a licencing agreement for RRx-001, a small molecule immunotherapy targeting CD47 – SIRP that is currently in Phase III trials in Small Cell Lung Cancer (“SCLC”).

• The US FDA granted orphan drug designation to RRx 001 for glioblastoma treatment in June 2019.

• Key cMyc Proto-Oncogene Protein Inhibitor pipeline therapies in the pre-clinical stage of development include ES-4000 (Escend Pharmaceuticals) and others.

Get a detailed analysis of the pipeline landscape @ cMyc Proto-Oncogene Protein Inhibitor Pipeline Analysis

cMyc Proto-Oncogene Protein Inhibitor: Overview

The MYC oncogene plays a role in the development of many human cancers. Recent discoveries about its expression and function have opened up new avenues for cancer treatment. Drug-like molecules could inhibit MYC activation by bromodomain proteins, resulting in tumour inhibition in vivo. Tumor growth can also be slowed by decoupling bioenergetic pathways involving glucose or glutamine metabolism from Myc-induced cellular biomass accumulation.

cMyc Proto-Oncogene Protein Inhibitor: Molecular Function

MYC mRNA produces Myc polypeptides, one of which begins at a CUG upstream of the canonical AUG start codon and another at an internal AUG. The Myc protein, derived from the canonical AUG, contains an N-terminal transcriptional regulatory domain, a nuclear localization signal, and a C-terminal region containing a basic DNA binding domain linked to a helix-loop-helix-leucine zipper (HLH-Zip) dimerization motif.

cMyc Proto-Oncogene Protein Inhibitor Pipeline Analysis: Drug Profiles

RRx-001: EpicentRx

Product Description

EpicentRx’s lead programme, RRx-001, is part of a portfolio of immunotherapeutic compounds that normalise the tumour microenvironment, activate the innate immune system’s tumour associated macrophages (TAMs), and sensitise solid tumours to standard therapies in small cell lung cancer (SCLC), glioblastoma, colorectal cancer, and other cancers.

Phase III

NCT03699956: EpicentRx launched a trial titled “A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer” in December 2018.

cMyc Proto-Oncogene Protein Inhibitor Pipeline Therapies and Key Companies 

• RRx-001: EpicentRx

• OMO- 103: Peptomyc

• WP-1066: Moleculin Biotech

• APTO 253:  Aptose Biosciences 

• ES-4000: Escend Pharmaceuticals

Find out the emerging therapies and companies @ cMyc Proto-Oncogene Protein Inhibitor Clinical Trials

cMyc Proto-Oncogene Protein Inhibitor Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

Scope of the Report

Coverage: Global

cMyc Proto-Oncogene Protein Inhibitor Key Players: EpicentRx, Peptomyc, Moleculin Biotech, Aptose Biosciences, Escend Pharmaceuticals, among others

cMyc Proto-Oncogene Protein Inhibitor Pipeline Therapies: RRx-001, OMO- 103, WP-1066, APTO 253, ES-4000, and others

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the cMyc Proto-Oncogene Protein Inhibitor Pipeline Report

• What cMyc Proto-Oncogene Protein Inhibitor Therapies are there?

• How many pharmaceutical companies are working on cMyc Proto-Oncogene Protein Inhibitor treatments?

• Which of these firms’ pharmaceuticals is the most widely used?

• How many cMyc Proto-Oncogene Protein Inhibitors medications is each company producing?

• How many drugs targeting cMyc Proto-Oncogene Protein Inhibitors are in the early, mid, or late stages of development?

• How many of the currently being developed therapies can be used alone or in combination with other treatments?

• What are the most important cMyc Proto-Oncogene Protein Inhibitor collaborations, mergers and acquisitions, and licencing practises?

Related Reports

RET (Ret Proto-Oncogene) Protein Inhibitor Pipeline Insights

Get a comprehensive analysis of RET (Ret Proto-Oncogene) Protein Inhibitor pipeline therapies and key companies, including Boston Pharmaceuticals, Mirati Therapeutics, Blueprint Medicines, Voronoi, GrayBug Vision, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/